References
- Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555
- Griffiths C. E. M., Dubertret L., Ellis C. N., Finlay A. Y., Finzi A. F., HO V. C., et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol 2004; 150((suppl 67))11–23
- Youn J. I., Moon S. E., Kim D. W., Park E. S., Moon D. C., Kim Y. K., et al. Cyclosporine in the treatment of psoriasis. J Dermatol Treat 1993; 4: 123–6
- Choi J. H., Kim K. J., Kim N. I., Kim T. Y., Park K. B., Youn J. I. Multicenter clinical study to evaluate the efficacy and safety of microemulsion cyclosporine (Cipol‐N®) in the treatment of psoriasis. Korean J Clin Pharmacol Ther 2002; 8: 184–95
- Krueger G., Koo J., Lebwohl M., Menter A., Stern R. S., Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patients–membership survey. Arch Dermatol 2001; 137: 280–4
- Finlay A. Y., Orthone J. P. Patient satisfaction with psoriasis therapies: An update and introduction to biologic therapy. J Cutan Med Surg 2004; 8: 310–20
- Finlay A. Y. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352–3
- Timonen P., Friend D., Abeywickrama K., Laburte C., von Graffenried B., Feutren G. Efficacy of low‐dose cyclosporin A in psoriasis: Results of dose‐finding studies. Br J Dermatol 1990; 122((suppl 36))33–9
- Laburte C., Grossman R., Abi‐Rached J., Abeywickrama K. H., Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366–75
- Ellis C. N., Fradin M. S., Messana J. M., Brown M. D., Siegel M. T., Voorhees J. J., et al. Cyclosporine for plaque‐type psoriasis. Results of a multidose, double‐blind trial. N Engl J Med 1991; 324: 277–84
- Feutren G., Abeywickrama K., Friend D., von Graffenried B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990; 122((suppl 36))57–69
- Christophers E., Mrowietz U., Henneicke H. H., Farber L., Welzel D. Cyclosporine in psoriasis: A multicenter dose‐finding study in severe plaque psoriasis. The German multicenter study. J Am Acad Dermatol 1992; 26: 86–90
- Ho V. C., Albrecht G., Vanaclocha F., Leon‐Dorantes G., Atakan N., Reitamo S., et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: A 1‐year multicenter, randomized study. Br J Dermatol 1999; 141: 283–91
- Faerber L., Braeutigam M., Weidinger G., Mrowietz U., Christophers E., Schulze H. J., et al. Cyclosporine in severe psoriasis. Results of a meta‐analysis in 579 patients. Am J Clin Dermatol 2001; 2: 41–7
- Lowe N. J., Wieder J. M., Rosenbach A., Johnson K., Kunkel R., Bainbridge C., et al. Long‐term low‐dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710–19
- Mihatsch M. J., Belghiti D., Bohman S. O., Porter K., Dubertret L., Feutren G., et al. Kidney biopsies in control or cyclosporin A‐treated psoriatic patients. International Kidney Biopsy Registry of Cyclosporin A (Sandimmun®) in Autoimmune Diseases. Br J Dermatol 1990; 122((suppl 36))95–100